Mucosal immunity can effectively prevent pathogen invasion of the mucosa at the initial stage of infection and inhibit pathogen replication within the body at later stages of infection. Therefore, the development of mucosal vaccines is of great significance for the prevention and control of infectious diseases. Intranasal vaccines can induce cellular, humoral, and mucosal immunity in the nasal mucosa and nasal-associated lymphoid tissue, producing secretory IgA, which plays a crucial role in preventing respiratory infections. However, the dilution of antigens by nasal mucus, clearance of antigens by cilia, and the barrier function of nasal epithelial cells in the nasal cavity can reduce the bioavailability of antigens and limit the efficacy of intranasal vaccines. This article reviews the structure of the nasal mucosal immune system and its mediated immune response, as well as intranasal vaccines that have been launched or are currently in clinical research, and explores the challenges faced in intranasal vaccine research.

Mucosal immunity can effectively prevent pathogen invasion of the mucosa at the initial stage of infection and inhibit pathogen replication within the body at later stages of infection. Therefore, the development of mucosal vaccines is of great significance for the prevention and control of infectious diseases. Intranasal vaccines can induce cellular, humoral, and mucosal immunity in the nasal mucosa and nasal-associated lymphoid tissue, producing secretory IgA, which plays a crucial role in preventing respiratory infections. However, the dilution of antigens by nasal mucus, clearance of antigens by cilia, and the barrier function of nasal epithelial cells in the nasal cavity can reduce the bioavailability of antigens and limit the efficacy of intranasal vaccines. This article reviews the structure of the nasal mucosal immune system and its mediated immune response, as well as intranasal vaccines that have been launched or are currently in clinical research, and explores the challenges faced in intranasal vaccine research.

In recent years, studies have shown that transplanted neural stem cells (NSCs) help neural tissues regenerate and return to normal through paracrine action rather than just replacing cells. Exosomes are essential paracrine mediators that can participate in cell communication through substance transmission. This review focuses on NSCs regulated by exosomes and their application in treatment of nervous system diseases, in order to provide important references for further research and clinical application of NSCs exosomes..

Objective:To evaluate the effects of a booster immunization with a candidate tetanus toxoid, reduced diphtheria toxoid and acellular pertussis combined vaccine (Tdap) in a rat model after primary vaccination with diphtheria, tetanus, acellular pertussis and Sabin strain inactivated poliovirus combined vaccine (DTacP-sIPV) or diphtheria, tetanus, acellular pertussis, inactivated poliovirus and haemophilus type b combined vaccine (DTacP-IPV/Hib) for further preclinical study.Methods:Wistar rats were randomly divided into three groups and respectively immunized with a self-developed DTacP-sIPV, a marketed DTacP-IPV/Hib and normal saline at 0, 1, and 2 months of age. Serum levels of antibody against each component in each group were detected before immunization and after each dose. A booster dose of the candidate Tdap was given 10 months after primary immunization. Serum levels of antibody against each component in each group were detected before, 1 month and 6 months after the booster immunization.Results:One month after three doses of primary immunization, the geometric mean titers (GMT, Log2) of antibodies against diphtheria toxoid (DT), tetanus toxoid (TT), pertussis toxin (PT), filamentous hemagglutinin (FHA) and pertactin (PRN) in the DTacP-sIPV group were 17.41, 18.34, 18.11, 19.93 and 13.91, respectively, and the seroconversion rates of these components all reached 100%. Ten months after primary immunization, the GMTs of antibodies against DT, TT, PT, FHA and PRN decreased to 15.17, 14.26, 13.60, 14.51 and 10.39, respectively, and the seroconversion rates remained above 89%. One month after booster immunization, the GMTs of antibodies against DT, TT, PT and FHA in the DTacP-sIPV and DTacP-IPV/Hib groups were 16.49/17.26, 16.80/17.63, 16.70/17.74 and 18.48/19.26, respectively, and the seroconversion rates of these components all reached 100% with no significant difference between the two groups ( P>0.05). The GMTs of anti-PRN antibody in the DTacP-sIPV and DTacP-IPV/Hib groups were 13.07 and 11.00, and the seroconversion rates were 100% and 88%, which were higher in the DTacP-sIPV group than in the DTacP-IPV/Hib group ( P<0.05). Six months after booster immunization, the GMTs of antibodies against DT, TT, PT, FHA and PRN in the DTacP-sIPV and DTacP-IPV/Hib groups decreased to 15.74/14.87, 15.07/15.14, 14.84/15.73, 16.62/16.37 and 11.44/9.96, respectively, and the seroconversion rates remained above 88%. Conclusions:Booster vaccination with the candidate Tdap vaccine induces humoral immune response following primary immunization with DTacP-sIPV or DTacP-IPV/Hib in the Wistar rat model, while the antibody titer decreases with time.